CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
click to rate
Posted by Two BlokesMon at 11:30 AM -
Filed in Stock
-
1 view
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) -
